Observational report describes mpox features in US adults aged 50+ versus younger adults

This observational report examined the epidemiologic and clinical features of mpox in adults in the United States, with a focus on comparing adults aged 50 years and older to other adults. The analysis also considered JYNNEOS vaccination status. The study design, sample size, and follow-up duration were not reported.

The main finding was a description of age group-specific features of mpox. No specific results, effect sizes, absolute numbers, p-values, or confidence intervals were provided for any comparisons between age groups or vaccination statuses. The direction of any differences was not reported.

Safety and tolerability data, including adverse events, were not reported. Key limitations, such as potential for confounding or selection bias, were not detailed. The funding source and author conflicts of interest were also not reported. Given the purely descriptive nature and lack of comparative results, this report offers limited direct clinical guidance but may inform broader surveillance understanding.